Zydus Lifesciences Limited (ZYDUSLIFE) receives final approval from USFDA for Ascorbic Acid Injection, gaining 180-day CGT exclusivity.
Zydus Lifesciences Limited (ZYDUSLIFE) announces a strategic option and license agreement with Mereo BioPharma for alvelestat in Alpha-1 Antitrypsin Deficien.
Zydus Lifesciences Limited (NSE: ZYDUSLIFE) moves up 5% intraday to ₹1177.2, nearing resistance at ₹1195. This move is backed by strong Q1 FY27 revenues.
Zydus Lifesciences Limited (ZYDUSLIFE) reports a 22% YoY revenue surge in Q1 FY27, driven by strong growth in India and North America.
Zydus Lifesciences Limited (ZYDUSLIFE) launches REVAHALE™, India’s first once-daily nebulised LAMA for COPD treatment, offering sustained 24-hour bronchodila.
Zydus Lifesciences Limited (ZYDUSLIFE) secures final approval from USFDA for Indocyanine Green for Injection, triggering 180-day CGT exclusivity.
Zydus Lifesciences Limited (ZYDUSLIFE) receives EIR from USFDA for its injectable facility with Voluntary Action Indicated (VAI) classification.
